Attenuation of chronic hypoxic pulmonary hypertension by simvastatin

Reda E. Girgis, Dechun Li, Xinhua Zhan, Joe G N Garcia, Rubin M. Tuder, Paul M Hassoun, Roger A Johns

Research output: Contribution to journalArticle

Abstract

The 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to improve multiple normal endothelial cell functions and inhibit vascular wall cell proliferation. We hypothesized that one such agent, simvastatin, would attenuate chronic hypoxic pulmonary hypertension. Male adult Sprague-Dawley rats were exposed (14 days) to normoxia (N), normoxia plus once-a-day administered simvastatin (20 mg/kg ip) (NS), hypoxia (10% inspired 02 fraction) (H), or hypoxia plus simvastatin (HS). Mean pulmonary artery pressure, measured in anesthetized, ventilated rats with an open-chest method, was reduced from 25 ± 2 mmHg in H to 18 ± in HS (P <0.001) but did not reach normoxic values (12 ± 1 mmHg). Similarly, right ventricular/left ventricular plus interventricular septal weight was reduced from 0.53 ± 0.02 in the H group to 0.36 ± 0.02 in the HS group (P <0.001). The increased hematocrit in H (0.65 ± 0.02) was prevented by simvastatin treatment (0.51 ± 0.01, P <0.001). Hematocrit was similar in N versus NS. Alveolar vessel muscularization and medial thickening of vessels 50-200 μM in diameter induced by hypoxia were also significantly attenuated in the HS animals. Lung endothelial nitric oxide synthase (eNOS) protein expression in the HS group was less than H (P <0.01) but was similar in N versus NS. We conclude that simvastatin treatment potently attenuates chronic hypoxic pulmonary hypertension and polycythemia in rats and inhibits vascular remodeling. Enhancement of lung eNOS expression does not appear to be involved in mediating this effect.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume285
Issue number3 54-3
StatePublished - Sep 1 2003

Fingerprint

Simvastatin
Pulmonary Hypertension
Nitric Oxide Synthase Type III
Hematocrit
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lung
Polycythemia
Coenzyme A
Hypoxia
Pulmonary Artery
Blood Vessels
Sprague Dawley Rats
Oxidoreductases
Thorax
Endothelial Cells
Cell Proliferation
Pressure
Weights and Measures

Keywords

  • 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition
  • Nitric oxide
  • Polycythemia
  • Pulmonary vascular remodeling
  • Small G proteins

ASJC Scopus subject areas

  • Physiology

Cite this

Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. / Girgis, Reda E.; Li, Dechun; Zhan, Xinhua; Garcia, Joe G N; Tuder, Rubin M.; Hassoun, Paul M; Johns, Roger A.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 285, No. 3 54-3, 01.09.2003.

Research output: Contribution to journalArticle

Girgis, Reda E. ; Li, Dechun ; Zhan, Xinhua ; Garcia, Joe G N ; Tuder, Rubin M. ; Hassoun, Paul M ; Johns, Roger A. / Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. In: American Journal of Physiology - Heart and Circulatory Physiology. 2003 ; Vol. 285, No. 3 54-3.
@article{c4061fb9dd9e4f0c805d7262c4322e21,
title = "Attenuation of chronic hypoxic pulmonary hypertension by simvastatin",
abstract = "The 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to improve multiple normal endothelial cell functions and inhibit vascular wall cell proliferation. We hypothesized that one such agent, simvastatin, would attenuate chronic hypoxic pulmonary hypertension. Male adult Sprague-Dawley rats were exposed (14 days) to normoxia (N), normoxia plus once-a-day administered simvastatin (20 mg/kg ip) (NS), hypoxia (10{\%} inspired 02 fraction) (H), or hypoxia plus simvastatin (HS). Mean pulmonary artery pressure, measured in anesthetized, ventilated rats with an open-chest method, was reduced from 25 ± 2 mmHg in H to 18 ± in HS (P <0.001) but did not reach normoxic values (12 ± 1 mmHg). Similarly, right ventricular/left ventricular plus interventricular septal weight was reduced from 0.53 ± 0.02 in the H group to 0.36 ± 0.02 in the HS group (P <0.001). The increased hematocrit in H (0.65 ± 0.02) was prevented by simvastatin treatment (0.51 ± 0.01, P <0.001). Hematocrit was similar in N versus NS. Alveolar vessel muscularization and medial thickening of vessels 50-200 μM in diameter induced by hypoxia were also significantly attenuated in the HS animals. Lung endothelial nitric oxide synthase (eNOS) protein expression in the HS group was less than H (P <0.01) but was similar in N versus NS. We conclude that simvastatin treatment potently attenuates chronic hypoxic pulmonary hypertension and polycythemia in rats and inhibits vascular remodeling. Enhancement of lung eNOS expression does not appear to be involved in mediating this effect.",
keywords = "3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition, Nitric oxide, Polycythemia, Pulmonary vascular remodeling, Small G proteins",
author = "Girgis, {Reda E.} and Dechun Li and Xinhua Zhan and Garcia, {Joe G N} and Tuder, {Rubin M.} and Hassoun, {Paul M} and Johns, {Roger A}",
year = "2003",
month = "9",
day = "1",
language = "English (US)",
volume = "285",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3 54-3",

}

TY - JOUR

T1 - Attenuation of chronic hypoxic pulmonary hypertension by simvastatin

AU - Girgis, Reda E.

AU - Li, Dechun

AU - Zhan, Xinhua

AU - Garcia, Joe G N

AU - Tuder, Rubin M.

AU - Hassoun, Paul M

AU - Johns, Roger A

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to improve multiple normal endothelial cell functions and inhibit vascular wall cell proliferation. We hypothesized that one such agent, simvastatin, would attenuate chronic hypoxic pulmonary hypertension. Male adult Sprague-Dawley rats were exposed (14 days) to normoxia (N), normoxia plus once-a-day administered simvastatin (20 mg/kg ip) (NS), hypoxia (10% inspired 02 fraction) (H), or hypoxia plus simvastatin (HS). Mean pulmonary artery pressure, measured in anesthetized, ventilated rats with an open-chest method, was reduced from 25 ± 2 mmHg in H to 18 ± in HS (P <0.001) but did not reach normoxic values (12 ± 1 mmHg). Similarly, right ventricular/left ventricular plus interventricular septal weight was reduced from 0.53 ± 0.02 in the H group to 0.36 ± 0.02 in the HS group (P <0.001). The increased hematocrit in H (0.65 ± 0.02) was prevented by simvastatin treatment (0.51 ± 0.01, P <0.001). Hematocrit was similar in N versus NS. Alveolar vessel muscularization and medial thickening of vessels 50-200 μM in diameter induced by hypoxia were also significantly attenuated in the HS animals. Lung endothelial nitric oxide synthase (eNOS) protein expression in the HS group was less than H (P <0.01) but was similar in N versus NS. We conclude that simvastatin treatment potently attenuates chronic hypoxic pulmonary hypertension and polycythemia in rats and inhibits vascular remodeling. Enhancement of lung eNOS expression does not appear to be involved in mediating this effect.

AB - The 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to improve multiple normal endothelial cell functions and inhibit vascular wall cell proliferation. We hypothesized that one such agent, simvastatin, would attenuate chronic hypoxic pulmonary hypertension. Male adult Sprague-Dawley rats were exposed (14 days) to normoxia (N), normoxia plus once-a-day administered simvastatin (20 mg/kg ip) (NS), hypoxia (10% inspired 02 fraction) (H), or hypoxia plus simvastatin (HS). Mean pulmonary artery pressure, measured in anesthetized, ventilated rats with an open-chest method, was reduced from 25 ± 2 mmHg in H to 18 ± in HS (P <0.001) but did not reach normoxic values (12 ± 1 mmHg). Similarly, right ventricular/left ventricular plus interventricular septal weight was reduced from 0.53 ± 0.02 in the H group to 0.36 ± 0.02 in the HS group (P <0.001). The increased hematocrit in H (0.65 ± 0.02) was prevented by simvastatin treatment (0.51 ± 0.01, P <0.001). Hematocrit was similar in N versus NS. Alveolar vessel muscularization and medial thickening of vessels 50-200 μM in diameter induced by hypoxia were also significantly attenuated in the HS animals. Lung endothelial nitric oxide synthase (eNOS) protein expression in the HS group was less than H (P <0.01) but was similar in N versus NS. We conclude that simvastatin treatment potently attenuates chronic hypoxic pulmonary hypertension and polycythemia in rats and inhibits vascular remodeling. Enhancement of lung eNOS expression does not appear to be involved in mediating this effect.

KW - 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition

KW - Nitric oxide

KW - Polycythemia

KW - Pulmonary vascular remodeling

KW - Small G proteins

UR - http://www.scopus.com/inward/record.url?scp=0041859249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041859249&partnerID=8YFLogxK

M3 - Article

C2 - 12750068

AN - SCOPUS:0041859249

VL - 285

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 3 54-3

ER -